New York, New York--(Newsfile Corp. - February 8, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Cannabis Deals Cross the Billion-Dollar Mark in Canada," featuring Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX).
To hear the NetworkNewsAudio version, visit: LINK
To read the original editorial, visit: LINK
Patents have been awarded in the United States and Australia and are pending in 40 more countries, as well as transnationally under the Patent Cooperation Treaty, as Lexaria's patent portfolio grows. The company has filed 19 patent applications that include both method and composition of matter claims. The patents issued in the United States and Australia include "Food and Beverage Compositions infused with Lipophilic Active Agents and Methods of Use thereof."
This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Lexaria has already had discussions with major pharmaceutical and other Fortune 500 companies regarding its technology. The smallest deal with any one of these could increase revenues by over $1 million; the largest by much, much more, according to CEO Chris Bunka in a recent interview (http://nnw.fm/jY9gG). Moreover, Lexaria's licensing model will generate revenues at very little cost, leaving 90 to 100 percent of revenues as profit.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit: www.NetworkNewsAudio.com
NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
New York, New York